CAR T Cell

3rd and 4th Generation CAR T-Cell Therapy: A Revolution in Cancer Treatment

Our company is at the forefront of developing cutting-edge 3rd and 4th generation CAR T-cell therapies, which represent a significant advancement in cancer immunotherapy. Unlike earlier generations, these CARs are engineered for enhanced precision and potency.

The 3rd generation CARs incorporate additional co-stimulatory domains, boosting their efficacy and persistence in targeting tumor cells. Meanwhile, 4th generation CARs, or TRUCKs (T cells Redirected for Universal Cytokine Killing), deliver cytokines directly to the tumor microenvironment, enhancing their anti-tumor response and minimizing off-target effects.

What sets us apart is our commitment to making this revolutionary treatment accessible in India. By developing CAR T-cells indigenously, we aim to reduce reliance on expensive imports, significantly lowering the cost of treatment. This approach aligns with the "Make in India" initiative and addresses the financial barriers many patients face, ensuring world-class cancer care for all.

With our expertise, we are not just advancing therapy but also democratizing it—bringing hope to countless cancer patients in India and beyond. Together, we can make cutting-edge immunotherapy a reality for everyone.

Limitations of Traditional Cancer Treatments:

For decades, cancer therapy depended on chemotherapy, radiation, or surgery. However, these methods often fail in relapsed or refractory cancers, especially leukemias and lymphomas.

The Rise of CAR T-Cell Therapy:

In the early 2010s, CD19-directed CAR T-cell therapy emerged as a game-changer, showing remarkable efficacy in B-cell hematological malignancies.
CAR T-cell therapy is a form of adoptive cell therapy (ACT), where a patient’s own immune cells are genetically modified to recognize and destroy cancer cells

FDA Approval and Clinical Success:

Impressive clinical outcomes have led to FDA approval of CAR T-cell therapy for various B-cell malignancies.
Many patients experience complete remission and significantly improved long-term survival.

Challenges and Limitations:

Despite its success, CAR T-cell therapy faces challenges such as antigen escape mediated relapse, limited persistence of CAR T-cells and high treatment costs.

The Need for CAR T-Cell Therapy in India:

With India home to 17% of the world’s population and registering over 700,000 new cancer cases annually, the demand for innovative cancer treatments is critical.
Establishing CAR T-cell therapy in India could significantly enhance cancer care, boost research, and strengthen the country’s healthcare economy.

Time Line of CAR T Cells

1993

First-generation CAR (CD3< )

2003

2nd generation CAR (CD28- CD3<)

2004

2nd generation CAR (4-1BB- CD3<)

2007

First IND for CD19 CAR

2011

4th generation CAR (TRUCKs)

2013

Demonstration of BCMA as a functional CAR target in myeloma (Preclinical)

2014

First in-human BCMA CAR T therapy clinical trial (NCI)

2017

FDA approval of CD19 CAR T therapy (Kymriah) for ALL

2017

Ide-cel (bb2121) granted Breakthrough-therapy designation award by FDA and PRIME by EHA

2017

FDA approval Of CD19 CAR T therapy (Yescarta) for NHL

2019

Cilta-cel (JNJ4528) granted Breakthrough-therapy designation award by FDA

2021

FDA approval of CD19 CAR T therapy (Liso-cel, Breyanzi) for NHL

2021

FDA approval Of Ide-cel (bb2121 ) for myeloma??